

Freedom of Information Request	FOI 23-520	20 October 2023
--------------------------------	------------	-----------------

Your request

You requested the following:

- For the 4 months from May to August 2023, how many patients received the following intra-vitreous treatments for any eye condition:
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Faricimab
 - Ranibizumab – Lucentis
 - Ranibizumab – Ongavia
- For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Faricimab
 - Ranibizumab – Lucentis
 - Ranibizumab – Ongavia

Our response

- Our response to question 1 is provided in the table below for May 2023 to August 2023.

Drug	May	June	July	August	Total
Faricimab	Not in use	68	195	244	507
Lucentis	95	60	38	25	218
Ongavia	42	95	142	187	466
Aflibercept (Eylea)	1071	975	891	850	3787
Total	1208	1198	1266	1306	4978

- Our response to question 2 is provided in the table below for May 2023 to August 2023.

Drug	May	June	July	August	Total
Faricimab	0	0	0	0	0
Lucentis	0	2	0	0	0
Ongavia	0	23	29	28	80

Aflibercept (Eylea)	44	8	19	10	37
Total	44	33	48	38	163

Please note that we do not hold data for the following drugs as they are not used within our clinic:

- Bevacizumab
- Brolucizumab
- Dexamethasone